More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.54B
EPS
-1.42
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
-0.080021
Previous close
$27.80
Today's open
$27.50
Day's range
$26.61 - $27.66
52 week range
$10.83 - $41.14
show more
CEO
Joshua Cohen
Employees
136
Headquarters
Cambridge, MA
Exchange
Nasdaq Global Select
Shares outstanding
128562904
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Amylyx Pharmaceuticals, Inc. (AMLX) Discusses LUCIDITY Results and Avexitide Potential in Post-Bariatric Hypoglycemia Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Discusses LUCIDITY Results and Avexitide Potential in Post-Bariatric Hypoglycemia Transcript
Seeking Alpha • Nov 15, 2026

Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.
Business Wire • Nov 14, 2026

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2026 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. ( AMLX ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Courtney O'Leary Justin Klee - Co-CEO & Director Camille Bedrosian - Chief Medical Officer Dan Monahan - Chief Commercial Officer James Frates - Chief Financial Officer Joshua Cohen - Co-Founder, Co-CEO & Director Conference Call Participants Jacob Ormes - TD Securities Equity Research Seamus Fernandez - Guggenheim Securities, LLC, Research Division Geoffrey Meacham - Citigroup Inc. Exchange Research Marc Goodman - Leerink Partners LLC, Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division Samuel Lee - Mizuho Securities USA LLC, Research Division Dina Ramadane - BofA Securities, Research Division Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division Christopher Chen - Robert W.
Seeking Alpha • Nov 6, 2026

Amylyx Pharmaceuticals Q3 Earnings Call Highlights
Amylyx Pharmaceuticals NASDAQ: AMLX plans to seek U.S. approval for its experimental treatment for post-bariatric hypoglycemia by the end of 2026, as it prepares for a potential launch in 2027 following positive late-stage trial results.
MarketBeat • Nov 5, 2026

Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results.
Business Wire • Nov 5, 2026

Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts.
Business Wire • Nov 4, 2026

Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences.
Business Wire • Nov 3, 2026

Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026.
Business Wire • Nov 2, 2026

11 Stocks Most Likely to See a Short Squeeze Rally
Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.
Schaeffers Research • Oct 12, 2026

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.
Business Wire • Oct 6, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Amylyx Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.